Akademik Veri Yönetim Sistemi
PEDIATRIC BLOOD & CANCER, cilt.55, sa.7, ss.1272-1277, 2010 (SCI-Expanded)
Background A number of clinical studies conducted in adults have demonstrated the prognostic significance of angiogenic factors in malignancies however only a limited number of studies have been conducted in children The aim of this study was to determine serum vascular endothelial growth factor (VEGF) endo statin and leptin levels in children with lymphoma and to investigate whether these factors provide prognostic information Procedure Serum samples from 36 children with lymphoma (non Hodgkin lymphoma (NHL) N = 21 Hodgkin lymphoma (HL) N = 15) were collected at diagnosis and during remission Serum samples were also collected from 18 healthy children as the control group Serum VEGF and endostatin levels were quantified by using enzyme linked immunosorbent assay (ELISA) and serum leptin by immunoradiometric assay Results The serum VEGF levels were found elevated in patients compared to controls (P = 0 033) while endostatin and leptin levels were lower in patients than in controls (endo statin 43 9 +/- 5 8 ng/ml vs 123 6 +/- 13 5 ng/ml P < 0 001 leptin 5 +/- 1 5 ng/ml vs 6 7 +/- 1 2 ng/ml P = 0 013) VEGF levels declined (pre 151 6 +/- 55 9 pg/ml vs post 16 2 +/- 7 9 pg/ml P = 0 041), while endostatin and leptin levels increased in patients who achieved remission (33 of 36 patients) when compared to pre treatment levels (endostatin pre 43 1 +/- 5 9 ng/ml vs post 65 9 +/- 6 8 ng/ml, P = 0 047 leptin pre, 5 3 +/- 1 6 ng/ml vs post 9 8 +/- 2 7 ng/ml P = 0 012) Serum VEGF endostatin and leptin levels were not predictive of survival Conclusion Serial measurement of serum VEGF endostatin and leptin levels could potentially be used to pre did response to treatment or progressive disease in children with lymphoma Pediatr Blood Cancer 2010 55 1272-1277 (C) 2010 Wiley Liss Inc